{
    "clinical_study": {
        "@rank": "104008", 
        "arm_group": {
            "arm_group_label": "vancomycin cohort"
        }, 
        "biospec_descr": {
            "textblock": "blood samples"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Recently, it was reported that when vancomycin levels are determined after port sampling,\n      levels can be falsely increased potentially leading to wrong dose adjustments.\n\n      The investigators conducted an in vitro experiment using several central venous port\n      devices, in which different flushing techniques were evaluated yielding residual vancomycin\n      levels of less than 0.5 mg/L.\n\n      In this study, the investigators want to evaluate this flushing technique in vivo in 15\n      patients admitted with catheter-related infection and treated with systemic vancomycin and\n      vancomycin antibiotic lock.\n\n      The purpose is to assess if correct flushing can avoid spurious vancomycin levels obtained\n      via port sampling."
        }, 
        "brief_title": "Optimalisation of Therapeutic Drug Monitoring (TDM) of Vancomycin in Patients With Central Venous Port Devices", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "condition": "Catheter-related Infection", 
        "condition_browse": {
            "mesh_term": "Catheter-Related Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adult patients,\n\n          -  having central venous port device,\n\n          -  treated with systemic vancomycin in combination with vancomycin antibiotic lock\n\n        Exclusion Criteria:\n\n          -  pregnant women,\n\n          -  children,\n\n          -  patients with 'do not resuscitate' (DNR) code"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Adult patients admitted for catheter related infection with methicillin-resistant\n        coagulase-negative staphylococci (MR-CNS) and treated with systemic vancomycin in\n        combination with vancomycin antibiotic lock via central venous port device."
            }
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01661361", 
            "org_study_id": "S54585"
        }, 
        "intervention": {
            "arm_group_label": "vancomycin cohort", 
            "intervention_name": "blood levels", 
            "intervention_type": "Procedure"
        }, 
        "intervention_browse": {
            "mesh_term": "Vancomycin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "vancomycin", 
            "levels", 
            "central venous port device", 
            "peripherally obtained levels", 
            "dose adjustments", 
            "TDM"
        ], 
        "lastchanged_date": "August 8, 2012", 
        "number_of_groups": "1", 
        "official_title": "Optimalisation of Therapeutic Drug Monitoring (TDM) of Vancomycin in Patients With Central Venous Port Devices", 
        "overall_contact": {
            "email": "isabel.spriet@uzleuven.be", 
            "last_name": "Isabel Spriet, PharmD PhD", 
            "phone": "0032 16 34 30 80"
        }, 
        "overall_contact_backup": {
            "email": "jan.verhaegen@uzleuven.be", 
            "last_name": "Jan Verhaegen, MD PhD", 
            "phone": "0032 16 33 22 11"
        }, 
        "overall_official": [
            {
                "affiliation": "Pharmacy Dpt, University Hospitals Leuven", 
                "last_name": "Isabel Spriet, PharmD PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Medical Diagnostic Sciences, University Hospitals Leuven", 
                "last_name": "Jan Verhaegen, MD PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Digestive ONcology, University Hosptials Leuven", 
                "last_name": "Hans Prenen, MD PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Internal Medicine, University Hospitals Leuven", 
                "last_name": "Willy Peetermans, MD PhD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "Pharmacy Dpt., University Hosptials Leuven", 
                "last_name": "Ludo Willems, PharmD PhD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "comparison of central (via port device) and peripherally obtained vancomycin levels: the difference, when using the new flushing technique, is allowed to be maximally 0.5 mg/L", 
            "safety_issue": "No", 
            "time_frame": "central and peripheral vancomycin levels will be obtained during steady state: this means starting from the 4th dose (= day 2) of vancomycin treatment.  Vancomycin is usually given during 14 days after the last positive blood culture."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01661361"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universitaire Ziekenhuizen Leuven", 
            "investigator_full_name": "Isabelle Spriet", 
            "investigator_title": "PharmD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Universitaire Ziekenhuizen Leuven", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universitaire Ziekenhuizen Leuven", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2012"
    }
}